UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $25.19 Million Stake in BioNTech SE (NASDAQ:BNTX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 19.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 221,080 shares of the company's stock after acquiring an additional 36,746 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.09% of BioNTech worth $25,192,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Jones Financial Companies Lllp raised its stake in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. increased its position in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after buying an additional 700 shares during the period. Allianz SE bought a new position in BioNTech in the 4th quarter worth approximately $90,000. Generali Investments CEE investicni spolecnost a.s. bought a new position in BioNTech in the 4th quarter worth approximately $137,000. Finally, AlphaCentric Advisors LLC bought a new position in BioNTech in the 4th quarter worth approximately $168,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Trading Down 4.5%

Shares of BNTX traded down $4.54 during trading hours on Friday, hitting $95.71. 1,493,516 shares of the stock traded hands, compared to its average volume of 910,728. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The firm has a market capitalization of $23.01 billion, a PE ratio of -45.58 and a beta of 1.35. The business has a fifty day moving average of $97.44 and a 200-day moving average of $108.12.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. The firm's revenue for the quarter was down 19.5% compared to the same quarter last year. Analysts expect that BioNTech SE will post -3.88 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BNTX. Canaccord Genuity Group restated a "buy" rating and set a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Wall Street Zen cut BioNTech from a "hold" rating to a "sell" rating in a research report on Friday. Morgan Stanley lowered their price objective on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. HC Wainwright restated a "buy" rating and set a $134.00 price objective on shares of BioNTech in a research report on Thursday, May 22nd. Finally, JPMorgan Chase & Co. lowered their price objective on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $140.14.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.